Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Roivant Sciences Ltd ROIV and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index change of 4 (SRI-4) at Week 52. Priovant plans to disclose the study data at a future date. "We saw…
#priovant #sle #mattgline #niu #dermatomyositis #phase2 #roivantsciences #vivekramaswamy #roivant